VNRX VolitionRx Ltd: Total Company Value-to-Revenue Ratio

VolitionRx Ltd. (VNRX) - corporate logo

Slow test adoption and challenges with insurance reimbursements are hindering the payback period for VolitionRx Limited (VNRX). The EV/Sales ratio trend demonstrates current volatility, where the 3005.81 level reflects the magnitude of the enterprise value-to-revenue valuation. VolitionRx Limited (VNRX) relies on patent protection for epigenetic analysis to create barriers for competitors, while the integration of liquid biopsy systems into B2B laboratories establishes high switching costs for clients.

VolitionRx Ltd (VNRX) - Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

VolitionRx Ltd. - analytical breakdowns and key metrics (VNRX)

- market price and analyst price targets:
Fundamental valuation:VolitionRx Ltd. (VNRX)
Flagship merchandise of VolitionRx

The current EV/Sales trend reflects the market valuation of VolitionRx Limited (VNRX) Nu.Q potential amid stringent FDA and CE-IVDR regulations. This metric compares the total enterprise value, including debt, against annual revenue, allowing investors to decouple speculative price growth from actual sales scaling, which is critical for assessing the capitalization sustainability of a biomedical startup.